V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 320002790 | 320001650 | 1.58 | 55.8 | Curative (C) | 2016-06-18 | 2016-06-18 | Cisplatin + Docetaxel +Fluorouracil | N | Y | 320016576 | CARBOPLATIN + RT |
| 320002791 | 320001651 | 1.79 | 87.2 | Palliative (P) | 2016-12-11 | 2016-12-12 | Cisplatin + Gemcitabine (D 1 & 8) | N | N | 320016593 | CARBOPLATIN + CETUXIMAB + FLUOROURACIL |
| 320002792 | 320001651 | 1.48 | 58.2 | Palliative (P) | 2014-03-14 | 2014-03-23 | Cisplatin + Docetaxel +Fluorouracil | 02 | N | 320016593 | CETUXIMAB + RT |
| 320002793 | 320001651 | 1.7 | 87.2 | Palliative (P) | 2015-06-28 | 2015-06-29 | PMB | N | N | 320016593 | ECARBOX |
| 320002794 | 320001651 | 1.72 | 69.7 | Adjuvant (A) | 2016-01-30 | 2016-02-07 | CARBOPLATIN + RT | 2 | N | 320016593 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320002795 | 320001652 | 1.75 | 66.7 | Adjuvant (A) | null | 2014-03-16 | CISPLATIN + ETOPOSIDE | N | N | 320016611 | CARBOPLATIN + RT |
| 320002796 | 320001652 | null | null | Neo-adjuvant (N) | 2014-11-08 | 2014-11-15 | Cabazitaxel | Y | N | 320016611 | POUT TRIAL |
| 320002797 | 320001652 | 1.7 | 0 | Adjuvant (A) | 2015-09-19 | 2015-09-28 | PEMBROLIZUMAB | 02 | N | 320016611 | CARBOPLATIN + RT |
| 320002798 | 320001653 | 1.7 | 86.3 | Palliative (P) | 2015-10-08 | 2015-10-13 | Carboplatin + Pemetrexed | 02 | N | 320016622 | RITUXIMAB |
| 320002799 | 320001654 | 1.67 | 0 | Curative (C) | 2015-03-01 | 2015-03-13 | CISPLATIN + GEMCITABINE | N | N | 320016624 | CISPLATIN + GEMCITABINE |
| 320002800 | 320001654 | 1.6 | null | Adjuvant (A) | 2016-01-08 | 2016-01-19 | CISPLATIN + GEMCITABINE | 02 | N | 320016624 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320002801 | 320001655 | 1.58 | 56.2 | Palliative (P) | 2014-04-04 | 2014-04-04 | Trial Unspecified | 02 | null | 320016641 | CETUXIMAB + RT |
| 320002802 | 320001656 | 1.56 | 67.799 | null | null | 2013-03-01 | Cetuximab + Radiotherapy Maint | null | null | 320016645 | CAPECITABINE + CISPLATIN |
| 320002803 | 320001657 | 1.73 | 19.5 | Neo-adjuvant (N) | 2016-05-10 | 2016-05-18 | Carboplatin + Vinorelbine Oral | N | N | 320016649 | NOT MATCHED |
| 320002805 | 320001659 | 1.53 | 63 | Palliative (P) | 2014-02-20 | 2014-02-21 | Doxorubicin + Ifosfamide | N | N | 320016658 | CAPECITABINE + CISPLATIN |
| 320002806 | 320001659 | 1.56 | null | Palliative (P) | null | 2013-04-06 | Cetuximab + Radiotherapy Load | N | N | 320016658 | BEVACIZUMAB + CARBO + PACLITAXEL |
| 320002807 | 320001660 | 1.62 | null | Palliative (P) | 2017-02-21 | 2017-02-28 | Carboplatin + Etoposide iv&po | 02 | N | 320016669 | CAPE + CARBOPLATIN + CETUXIMAB |
| 320002808 | 320001661 | 1.62 | 65 | Adjuvant (A) | 2014-08-03 | 2014-09-06 | CHOP R - 21 days | N | N | 320016672 | ICON8B TRIAL |
| 320002809 | 320001662 | 1.91 | 62.3 | Curative (C) | 2013-03-11 | 2013-03-12 | Doxorubicin chemoembolisation | 02 | N | 320016675 | CAPECITABINE + OXALIPLATIN |
| 320002810 | 320001662 | null | null | null | 2015-08-19 | 2015-08-24 | Carboplatin + Etoposide IV 3 day | N | null | 320016675 | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL |
| 320002811 | 320001663 | null | 85.3 | Curative (C) | null | 2014-01-03 | BEVACIZUMAB + CARBO | null | null | 320016685 | DE-ESCALATE TRIAL |
| 320002812 | 320001663 | 1.48 | 79 | Adjuvant (A) | null | 2014-01-07 | Capecitabine | N | Y | 320016685 | MPV |
| 320002813 | 320001663 | 1.87 | 69.5 | Palliative (P) | 2018-12-18 | 2018-12-18 | Cisplatin + Gemcitabine (D 1 & 8) | N | N | 320016685 | CARBO + FLUOROURACIL |
| 320002814 | 320001664 | 1.63 | 45 | Palliative (P) | 2014-03-20 | 2014-03-25 | Carboplatin + Pemetrexed | 02 | N | 320016701 | EC |
| 320002815 | 320001665 | null | 46 | Palliative (P) | 2017-03-07 | 2017-04-03 | Cisplatin + Docetaxel +Fluorouracil | N | N | 320016706 | CETUXIMAB + RT |
| 320002816 | 320001666 | 1.55 | 52.3 | Curative (C) | 2013-12-29 | 2014-01-11 | Bevacizumab + CARBOPLATIN + PACLITAXEL | 2 | N | 320016707 | POUT TRIAL |
| 320002817 | 320004886 | 1.79 | 69.3 | Neo-adjuvant (N) | 2017-03-06 | 2017-03-08 | CAPECITABINE + TEMOZOLOMIDE | N | N | 320016719 | CARBOPLATIN + VINORELBINE |
| 320002818 | 320004886 | null | 120 | null | 2014-04-30 | 2014-05-16 | Capecitabine + Oxaliplatin 21day | null | N | 320016719 | CETUXIMAB + RT |
| 320002819 | 320006933 | 1.57 | 61.8 | Neo-adjuvant (N) | 2016-04-19 | 2016-05-10 | BEVACIZUMAB + CARBO | N | N | 320016728 | CARBOPLATIN + CETUXIMAB + FLUOROURACIL |
| 320002820 | 320001667 | 1.72 | 56.6 | Palliative (P) | 2017-07-07 | 2017-09-03 | Cetuximab +Cisplatin + FU (Cycle 1) | N | N | 320016729 | BLEOMYCIN |
| 320002821 | 320001668 | 1.77 | null | Palliative (P) | null | 2014-11-17 | CETUXIMAB + RT | null | null | 320016730 | CISPLATIN + GEMCITABINE |
| 320002822 | 320001668 | null | null | Neo-adjuvant (N) | 2017-04-13 | 2017-05-04 | CETUXIMAB + RT | N | N | 320016730 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320002823 | 320006291 | 1.59 | 63 | Neo-adjuvant (N) | 2017-08-19 | 2017-09-14 | Carboplatin+Fluorouracil 4 or 5 day | N | N | 320016743 | CAPECITABINE + CISPLATIN |
| 320002824 | 320001669 | 1.57 | 74.2 | Neo-adjuvant (N) | 2017-02-16 | 2017-02-21 | Ipilimumab | N | N | 320016750 | CETUXIMAB + CISPLATIN + FLUOROURACIL |
| 320002825 | 320001670 | 1.63 | 66.8 | Not known (9) | 2016-05-23 | 2016-05-30 | PEMBROLIZUMAB | N | N | 320016751 | CISPLATIN + ETOPOSIDE |
| 320002826 | 320001671 | 1.64 | 67.7 | Palliative (P) | 2014-06-24 | 2014-07-07 | Capecitabine + Oxaliplatin 21day | N | N | 320016758 | PAZOPANIB |
| 320002827 | 320001672 | 1.6 | 88.6 | null | 2014-09-21 | 2015-08-31 | Paclitaxel 7 day | 02 | N | 320016764 | FEC |
| 320002828 | 320004888 | null | 51.9 | null | 2017-04-15 | 2017-04-30 | Carboplatin+Fluorouracil 4 or 5 day | N | null | 320016766 | BCG |
| 320002829 | 320001673 | 1.63 | 66 | Neo-adjuvant (N) | 2016-12-01 | 2016-12-12 | CARBOPLATIN + RT | N | N | 320016767 | CHOP R |
| 320002830 | 320001673 | 1.6 | 57.9 | Palliative (P) | 2014-04-27 | 2014-05-09 | Mitomycin Intravesical | 02 | N | 320016767 | BEVACIZUMAB + CARBO + PACLITAXEL |
| 320002831 | 320006292 | 1.67 | null | Palliative (P) | 2016-05-30 | 2016-05-30 | Cisplatin + Gemcitabine (D 1 & 8) | N | N | 320016771 | PEMBROLIZUMAB |
| 320002832 | 320001674 | null | 58.55 | Palliative (P) | 2017-08-06 | 2017-08-13 | Cisplatin + Fluorouracil + RT 5day | N | N | 320016774 | PACLITAXEL |
| 320002833 | 320001675 | 1.68 | 63.8 | Curative (C) | 2014-10-01 | 2014-10-27 | CISPLATIN + GEMCITABINE | N | N | 320016783 | ECX |
| 320002834 | 320001676 | 1.7 | 110 | null | 2013-07-11 | 2014-07-27 | Folfirinox/ Folfoxiri | 2 | N | 320016794 | POUT TRIAL |
| 320002835 | 320001677 | 1.7 | 46 | Adjuvant (A) | 2013-10-29 | 2013-10-29 | BLEOMYCIN | 2 | N | 320016795 | CAPECITABINE + OXALIPLATIN |
| 320002836 | 320001678 | 1.61 | 55.8 | null | 2016-04-11 | 2016-04-11 | STS Rhabdomyosarcoma RMS 2005 IVADo | 2 | N | 320016797 | CETUXIMAB + RT |
| 320002837 | 320001678 | 1.64 | 54.2 | Disease modification (D) | 2018-07-18 | 2018-07-18 | BCG Intravesical | 02 | N | 320016797 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 320002838 | 320001679 | 1.71 | 82 | Neo-adjuvant (N) | 2016-07-13 | 2016-07-20 | Cisplatin + Fluorouracil + RT 5day | N | N | 320016808 | TRABECTEDIN |
| 320002839 | 320001680 | 1.58 | 38.1 | Curative (C) | 2013-04-20 | 2013-05-04 | CISPLATIN + GEMCITABINE | 2 | N | 320016815 | CISPLATIN + FLUOROURACIL + RT |
| 320002840 | 320001680 | 1.59 | 72.4 | Curative (C) | 2017-01-01 | 2017-01-01 | CISPLATIN + ETOPOSIDE | N | N | 320016815 | CISPLATIN + DOCETAXEL + FLUOROURACIL |